SCYNEXIS Inc reports results for the quarter ended September 30 - Earnings Summary

• SCYNEXIS Inc SCYX.OQ reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -6 cents. The mean expectation of three analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -21 cents to -18 cents per share.

• Revenue fell 49.4% to $334.00 thousand from a year ago; analysts expected $147.67 thousand.

• SCYNEXIS Inc's reported EPS for the quarter was a loss of 17 cents​.

• The company reported a quarterly loss of $8.59 million.

• SCYNEXIS Inc shares had fallen by 18.1% this quarter and lost 47.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 33.3% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for SCYNEXIS Inc is $4.00, about 84.2% above its last closing price of $0.63

This summary was machine generated from LSEG data November 6 at 07:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)